1. Japan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
StemCell Institute

StemCell Institute

TTSE:7096
716.00
JPY
-5.00
(-0.69%)
7.71BMarket Cap
Nov 10Next Earn
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
84.08
112.22
172.22
144.8
175.93
204.1
242.15
261.6
278.38
- -
Basic EPS, GAAP
6.79
13.94
28.51
6.41
13.2
19.33
30.35
37.67
15.44
- -
Free Cash Flow per Basic Share
29.69
35.25
61.93
-16.88
26.14
3.88
12.98
-10.45
-44.89
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
24.98
0.02
- -
Book Value per Share
81.93
95.87
122.95
129.04
205.33
224.33
262.78
258.35
266.34
- -
Tangible Book Value per Share
80.38
95.24
122.13
127.48
202.93
221.93
258.72
245.34
243.93
- -
Basic Weighted Avg Shares
10
10
10
10
10
10
10
10
10
10
Sales/Revenue/Turnover
862
1,150
1,676
1,410
1,782
2,091
2,481
2,679
2,811
- -
Operating Margin (%)
12.78
18.78
22.81
6.16
12.74
14.23
16.68
15.62
7.21
- -
Depreciation Expense
35
35
32
33
97
105
121
128
157
- -
Net Income, GAAP
70
143
277
62
134
198
311
386
156
- -
Effective Tax Rate (%)
37.46
33.55
27.46
31.79
37.09
29.01
29.54
31.8
39.85
- -
Profit Margin (%)
8.07
12.42
16.55
4.42
7.5
9.47
12.53
14.4
5.55
- -
Working Capital
700
845
1,046
561
1,127
1,114
755
854
781
- -
LT Debt
- -
- -
- -
- -
- -
5
7
452
403
- -
Total Equity
840
982
1,260
1,322
2,104
2,299
2,693
2,628
2,682
- -
Return on Invested Capital (%)
- -
15.09
23.24
4.45
8.15
9.29
11.31
9.4
3.76
- -
Return on Capital (%)
- -
15.68
24.75
4.83
7.81
8.98
12.42
13.22
5.84
- -
Return on Common Equity (%)
- -
15.68
24.75
4.83
7.81
9
12.46
14.5
5.87
- -

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
62
71
- -
LT Borrowings
409
377
- -
LT Finance Leases
- -
26
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
10
10
10
Market Capitalization
9,486
7,714
7,291

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
5,284
5,314
- -
Cash, Cash Equivalents & STI
3,067
2,834
- -
Accounts Receivable, Net
2,077
2,337
- -
Inventories
58
54
- -
Total Current Liabilities
4,323
4,532
- -
Payables & Accruals
- -
- -
- -
ST Debt
62
71
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
17.03%
2.06%
Free Cash Flow
- -
6.23%
323.42%
Net Income, GAAP
- -
36.8%
-59.59%
Sales/Revenue/Turnover
- -
15.07%
4.93%
Total Cash Common Dividend
- -
- -
-99.91%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
2,679
2026
- -
- -
- -
- -
2,811
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
37.67
2026
- -
- -
- -
- -
15.44
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
24.98
2026
- -
- -
- -
- -
0.02
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Takafumi Shimizu
Full Time Employees
136
Sector
Health technology
Industry
Biotechnology
Address
Tokyu Toranomon Building Tokyo TY Japan 105-0001
IPO Date
Jun 25, 2021
Website
stemcell.co.jp
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
StemCell Institute Inc. (7096.T) operates as Japan's leading private cord blood bank, specializing in the collection, processing, separation, cryopreservation, and storage of umbilical cord blood and cord tissue cells for regenerative medicine and cell therapy applications; it offers HOPECELL, a unique family banking service that preserves both umbilical cord and cord blood together, providing customers with access to stem cells for potential treatments such as leukemia and cerebral palsy. The company also engages in research and development of stem cell-based medical treatments, blood vessel cell banking, and related investments in regenerative medicine and femtech sectors; its services include ultra-low temperature storage in state-of-the-art cell processing centers in Tokyo and Yokohama, with over 80,000 cord blood units preserved, representing more than 99% market share among private banks in Japan. Founded in 1999 and headquartered in Tokyo at 2F Tokyu Toranomon Building, 1-21-19 Toranomon, Minato-ku, the firm maintains ISO 9001 certification for its facilities and operates as a subsidiary of Nihon Trim Group, a Tokyo Stock Exchange-listed entity, primarily serving expectant families across Japan through nationwide obstetric partnerships. In recent developments, StemCell Institute expanded its processing capabilities with a new Yokohama cell processing center in 2020 for dedicated cord tissue handling; it continues to lead in domestic private bank releases of cord blood units for actual treatments and invests in sustainable growth through strategic alliances in regenerative fields as of 2025.